EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma

Cristiane Bergerot iD, Sun Young Rha, Sumanta Pal, Piotr Koralewski, Daniil Stroyakovskiy, Boris Alekseev, Francis Parnis, Daniel Castellano, Jae Lyun Lee, Kaisa Sunela, Tudor Ciuleanu, Daniel Heng und 6 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyac142 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Oncologist, 2023. Verfasst von Cristiane Bergerot und 17 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Unity de Ensino e Pesquisa, Centro de Câncer de Brasília, Brasília, DF, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RTI Health Solutions and Eisai, Eisai, Merck Sharp & Dohme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preserving health-related quality of life (HRQOL) is an important goal during renal cell carcinoma treatment. We report HRQOL outcomes from a phase II trial (NCT03173560). Patients and Methods HRQOL data were collected during a multicenter, randomized, open-label phase II study comparing the safety and efficacy of 2 different starting doses of lenvatinib (18 mg vs. 14 mg daily) in combination with everolimus (5 mg daily), following one prior vascular endothelial growth factor–targeted treatment. HRQOL was measured using 3 different instruments—FKSI-DRS, EORTC QLQ-C30, and EQ-5D-3L—which were all secondary endpoints. Change from baseline was assessed using linear mixed-effects models. Deterioration events for time to deterioration (TTD) analyses were defined using established thresholds for minimally important differences in the change from baseline for each scale. TTD for each treatment arm was estimated using the Kaplan–Meier method.

Results

Baseline characteristics of the 343 participants randomly assigned to 18 mg lenvatinib (n = 171) and 14 mg lenvatinib (n = 172) were well balanced. Least-squares mean estimates for change from baseline were favorable for the 18 mg group over the 14 mg group for the FKSI-DRS and most EORTC QLQ-C30 scales, but differences between treatments did not exceed the minimally important thresholds. Median TTD was longer among participants in the 18 mg group than those in the 14 mg group for most scales.

Conclusions

Participants who received an 18 mg lenvatinib starting dose had favorable HRQOL scores and longer TTD on most scales compared with those who received a 14 mg starting dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAntineoplastic AgentsHumansEverolimusQuality of LifeVascular Endothelial Growth Factor APhenylurea CompoundsQuinolines

Stichwörter der Autor:innen

EORTC QLQ-C30FKSI-DRSVEGFpatient-reported outcomesphase II

Substanzen

EverolimusVascular Endothelial Growth Factor AAntineoplastic AgentslenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Instituto Unity de Ensino e Pesquisa, Centro de Câncer de Brasília, Brasília, DF, Brazil.
  • Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea.
  • Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Szpital Specjalistyczny Ludwika Rydygiera, Kraków, Poland.
  • Moscow City Oncology Hospital #62 of Moscow Healthcare Department, Moscow, Russia.
  • P.A. Hertzen Moscow Oncological Research Institute, Moscow, Russia.

ORCID-Profile: Cristiane Bergerot

Förderung

  • RTI Health Solutions and Eisai
  • Eisai
  • Merck Sharp & Dohme
  • Merck

Zitieren

APA

Bergerot, C., Young Rha, S., Pal, S., Koralewski, P., Stroyakovskiy, D., Alekseev, B., Parnis, F., Castellano, D., Lyun Lee, J., Sunela, K., Ciuleanu, T., Heng, D., Glen, H., Wang, J., Bennett, L., Pan, J., O'Hara, K., & Puente, J. (2023). Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyac142

Vancouver

Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, et al. Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma. The Oncologist. 2023. doi:10.1093/oncolo/oyac142

BibTeX
@article{Bergerot2023,
  author = {Bergerot, Cristiane and Young Rha, Sun and Pal, Sumanta and Koralewski, Piotr and Stroyakovskiy, Daniil and Alekseev, Boris and Parnis, Francis and Castellano, Daniel and Lyun Lee, Jae and Sunela, Kaisa and Ciuleanu, Tudor and Heng, Daniel and Glen, Hilary and Wang, Jinyi and Bennett, Lee and Pan, Janice and O'Hara, Karen and Puente, Javier},
  title = {Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyac142}
}
Kostenlos starten →